Proteonomix (PROT) Updates Status of Clinical Trial
(firmenpresse) - MOUNTAINSIDE, NJ -- (Marketwire) -- 02/28/12 -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today progress regarding human trials on its product, UMK-121.
Proteonomix has been informed that patient screening has commenced at the
Proteonomix, CTO, Steven Byle stated that "We are excited to see our years of hard work and research investment coming to fruition. We at Proteonomix consider ourselves fortunate to be involved in a business that has the opportunity to try and help people in such dire need. We look forward to monitoring the trials going forward."
It should be noted that effective March 7, 2012, a will require that informed consent documents state that the clinical trial has been or will be registered and the results will be published in the National Institutes of Health/National Library of Medicine clinical trials database (). After such date, it is anticipated that any person may find out additional information and follow the progress of these human trials on this government informational site.
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit , , and .
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.02.2012 - 13:20 Uhr
Sprache: Deutsch
News-ID 119345
Anzahl Zeichen: 0
contact information:
Town:
MOUNTAINSIDE, NJ
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 332 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Proteonomix (PROT) Updates Status of Clinical Trial"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteonomix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
